AbbVie Inc. (ABBV)
| Previous close | 167.80 |
| Open | 167.66 |
| Bid | 166.81 x 800 |
| Ask | 166.87 x 800 |
| Day's range | 165.59 - 169.14 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,617,229 |
| Market cap | 295.088B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 61.27 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 6.20 (3.69%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- Reuters
UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.
- Zacks
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
- Zacks
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
